http://www.amgennews.com/index.php en pmannle@amgen.com Copyright 2012 2012-01-26T22:31:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgens_full_year_2011_revenue_increased_4_percent_to_156_billion_and_adjust/ http://www.amgennews.com/index.php/2008NewsService/amgens_full_year_2011_revenue_increased_4_percent_to_156_billion_and_adjust/#When:22:31:00Z Full Year 2011 GAAP EPS Decreased 16 Percent to $4.04 Due to a One-Time Charge 2012 Total Revenue and Adjusted EPS Expected to be in the Range of $16.1-$16.5 Billion and $5.90-$6.15, Respectively Amgen reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010.  For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010. Press Releases 2012-01-26T22:31:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_acquire_micromet/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_acquire_micromet/#When:17:38:00Z Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies Micromet’s Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types All-Cash Transaction Values Micromet at $1.16 Billion THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) and Micromet, Inc.  (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors. Press Releases 2012-01-26T17:38:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2011_fourth_quarter_and_full_year_financial_resu/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2011_fourth_quarter_and_full_year_financial_resu/#When:22:06:00Z THOUSAND OAKS, Calif., Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Standard Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. Press Releases 2012-01-24T22:06:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_present_at_the_30th_annual_jp_morgan_global_healthcare_conference/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_present_at_the_30th_annual_jp_morgan_global_healthcare_conference/#When:19:12:00Z THOUSAND OAKS, Calif., Jan. 4, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at the Westin St. Francis in San Francisco, Calif.  Robert A. Bradway, president and chief operating officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. Press Releases 2012-01-04T19:12:00+00:00 http://www.amgennews.com/index.php/2008NewsService/fda_to_review_potential_new_use_of_xgeva_denosumab_at_oncologic_drugs_advis/ http://www.amgennews.com/index.php/2008NewsService/fda_to_review_potential_new_use_of_xgeva_denosumab_at_oncologic_drugs_advis/#When:19:09:00Z THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases. Press Releases 2011-12-29T19:09:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_and_watson_announce_collaboration_to_develop_and_commercialize_oncolo/ http://www.amgennews.com/index.php/2008NewsService/amgen_and_watson_announce_collaboration_to_develop_and_commercialize_oncolo/#When:21:27:01Z THOUSAND OAKS, Calif. and PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients. Press Releases 2011-12-19T21:27:01+00:00 http://www.amgennews.com/index.php/2008NewsService/kevin_sharer_amgen_chairman_and_ceo_announces_plan_to_retire_with_robert_br/ http://www.amgennews.com/index.php/2008NewsService/kevin_sharer_amgen_chairman_and_ceo_announces_plan_to_retire_with_robert_br/#When:00:39:01Z Roger Perlmutter to Retire as EVP of Research and Development with Sean Harper to Assume the Role on February 13, 2012 THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/—Kevin W. Sharer, chairman and chief executive officer of Amgen (NASDAQ:AMGN) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen.  To facilitate an orderly transition process, Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the Company’s Board of Directors until December 31, 2012, at which time he will retire from the Board and from the Company.  Robert Bradway, currently president and chief operating officer, will become CEO on May 23, 2012.  It is the intention of the Board of Directors to elect Bradway chairman of the Board when Sharer retires from that position at the end of 2012.  The Board will also elect a lead independent director at that time. Press Releases 2011-12-15T00:39:01+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_2012_first_quarter_dividend/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_2012_first_quarter_dividend/#When:00:37:00Z THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the first quarter of 2012. This represents an approximate 29 percent increase from that paid in the previous two quarters. The dividend will be paid on March 7, 2012 to all stockholders of record as of the close of business on Feb. 15, 2012.  Press Releases 2011-12-15T00:37:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_final_results_of_its_tender_offer/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_final_results_of_its_tender_offer/#When:18:15:00Z THOUSAND OAKS, Calif., Dec. 14, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011. Press Releases 2011-12-14T18:15:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_presents_final_results_from_the_largest_phase_3_open_label_study_asse/ http://www.amgennews.com/index.php/2008NewsService/amgen_presents_final_results_from_the_largest_phase_3_open_label_study_asse/#When:22:22:00Z Additional Key Nplate Data Also Presented at American Society of Hematology Annual Meeting THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced that data from several key Nplate® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011, in San Diego. Of note, final results from the international, Phase 3, open-label, single-arm ‘209 study evaluating the safety and efficacy of Nplate in adults with primary immune thrombocytopenia (ITP) demonstrated that Nplate induced a rapid platelet response in adult ITP patients with low platelet counts or bleeding symptoms and maintained a consistent safety profile (Abstract No. 3279). Press Releases 2011-12-13T22:22:00+00:00